Cooperative Agreement U44AI152970

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,927 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop and characterize broadly neutralizing human monoclonal antibodies (mAbs) as potential therapeutics to inhibit human cytomegalovirus (CMV) infection and dissemination. The key objectives of this 1-year project are to: 1) identify neutralizing CMV mAbs targeting...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $232,415 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of California, Davis (UC Davis) to develop and test a highly potent monoclonal antibody that can neutralize the cytomegalovirus (CMV)-encoded IL-10 immunomodulatory protein. The goal is to evaluate if this antibody can provide significant protection against primary CMV infection, either alone or in combination with...

This $650,000 federal Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) will fund a Phase 2A/2B clinical study at the Sloan-Kettering Institute for Cancer Research to evaluate the use of the IFN-gamma neutralizing monoclonal antibody emapalumab as a prophase therapy for pediatric patients with newly diagnosed aplastic anemia. The study aims to develop an algorithm to identify patients most likely to respond favorably to immune suppression therapy,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $8,276,078 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) on July 12, 2024. The grant funds a 5-center randomized controlled trial to evaluate preemptive therapy (PET) versus antiviral prophylaxis (AP) for preventing cytomegalovirus (CMV) disease in 360 CMV donor-positive/recipient-negative kidney transplant...

This Federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,664 to the Research Institute at Nationwide Children's Hospital (RINCH) to conduct research on adaptive immune responses to congenital and postnatal cytomegalovirus (CMV) infection. The key objectives are to: 1) Identify pathways that inhibit Th1 cell responses after congenital CMV (cCMV) infection, by...

This National Cancer Institute (NCI) Project Grant award under the Cancer Treatment Research program (CFDA 93.395) provides $627,061 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and evaluate the efficacy of novel oncolytic herpes simplex virus (oHSV) immunotherapies for the treatment of glioblastoma (GBM), a fatal form of brain cancer. The key objectives are to determine if agents inhibiting the immunosuppressive adenosine (ADO)...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai. The grant, titled "Optimization of Novel Inhibitors of Human Cytomegalovirus (CMV)," aims to develop new therapeutic approaches to treat CMV infections, which can lead to severe health complications, especially in immunocompromised populations. The key objectives of the...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $430,604 to Imperial College of Science, Technology and Medicine in the United Kingdom to conduct research on the role of placental macrophages in cytomegalovirus (CMV) infection at the maternal-fetal interface. The key objectives are to: 1) investigate the temporal response of placental macrophages (Hofbauer...

This $188,169 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the University of California, Davis in developing a gene therapy vector using the adeno-associated virus (AAV) system to treat Kaposi's sarcoma-associated herpesvirus (KSHV)-related malignancies. The project aims to complete proof-of-concept studies evaluating the biological activity and efficacy of this targeted gene therapy approach in killing KSHV-infected cancer...

This Project Grant award of $832,910.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research at the University of Washington to identify immune system factors that predict the risk of cytomegalovirus (CMV) disease in orthotopic liver transplant patients. The research aims to characterize the neutralizing and non-neutralizing antibody response to CMV, map the CMV-specific B cell...